Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2013

01-12-2013 | Original Article

Use of Exclusive Enteral Nutrition Is Just as Effective as Corticosteroids in Newly Diagnosed Pediatric Crohn’s Disease

Authors: Jason Soo, Bushra A. Malik, Justine M. Turner, Rabin Persad, Eytan Wine, Kerry Siminoski, Hien Q. Huynh

Published in: Digestive Diseases and Sciences | Issue 12/2013

Login to get access

Abstract

Background

The efficacy of exclusive enteral nutrition (EEN) in induction of remission in pediatric Crohn’s disease (CD) is reported to be equivalent to that of corticosteroids (CS).

Aims

Our objective was to compare the efficacy of EEN and CS in inducing remission in pediatric onset CD and the effects of the treatment on nutritional status and bone mineral density (BMD).

Methods

Medical charts were retrospectively studied for patients diagnosed with CD between 2000 and 2010 at the Stollery children’s hospital in Edmonton, Alberta. Anthropometric and dual-energy X-ray absorptiometry (DXA) data were collected to assess effects of therapy; clinical remission, relapse, and severity were defined on the basis of the pediatric Crohn’s disease activity index.

Results

To induce remission at first presentation, 36 patients (mean age 12.9 years) received EEN and 69 (mean age 11.2 years) received CS. Remission (88.9 % in the EEN group versus 91.3 % in the CS group (p = 0.73) at 3 months) and relapse (40.6 vs. 28.6 %, respectively (p = 0.12) over 12 months) were similar in both treatment groups. Thirty-four patients had paired DXA scans at the time of diagnosis and one year later: 16 given EEN and 18 given CS. Change in BMD spine z-scores based on bone age adjusted for height and chronological age was greater for EEN patients but not statistically significant (Δz-score 0.30 vs. 0.03, p = 0.28).

Conclusions

EEN has similar efficacy to corticosteroids; however, EEN may lead to better BMD accrual. EEN should be preferred to corticosteroids as first-line therapy for induction of remission in pediatric CD.
Literature
1.
go back to reference Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58:1490–1497.PubMedCrossRef Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58:1490–1497.PubMedCrossRef
2.
go back to reference Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn’s disease. Gut. 1993;34:939–943.PubMedCrossRef Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn’s disease. Gut. 1993;34:939–943.PubMedCrossRef
3.
go back to reference Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther. 2007;26:795–806.PubMedCrossRef Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther. 2007;26:795–806.PubMedCrossRef
4.
go back to reference Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev. 2005;3:CD003873. Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev. 2005;3:CD003873.
5.
go back to reference Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr. 2010;50:S1–S13.PubMedCrossRef Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr. 2010;50:S1–S13.PubMedCrossRef
6.
go back to reference Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:1124–1129.PubMedCrossRef Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:1124–1129.PubMedCrossRef
7.
go back to reference Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children.[see comment]. J Pediatr Gastroenterol Nutr. 2000;31:8–15.PubMedCrossRef Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children.[see comment]. J Pediatr Gastroenterol Nutr. 2000;31:8–15.PubMedCrossRef
8.
go back to reference Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995;10:250–256.PubMedCrossRef Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995;10:250–256.PubMedCrossRef
9.
go back to reference Saha MT, Ruuska T, Laippala P, Lenko HL. Growth of prepubertal children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;26:310–314.PubMedCrossRef Saha MT, Ruuska T, Laippala P, Lenko HL. Growth of prepubertal children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;26:310–314.PubMedCrossRef
10.
go back to reference Walker-Smith JA. Management of growth failure in Crohn’s disease. Arch Dis Child. 1996;75:351–354.PubMedCrossRef Walker-Smith JA. Management of growth failure in Crohn’s disease. Arch Dis Child. 1996;75:351–354.PubMedCrossRef
11.
go back to reference Day AS, Stephenson T, Stewart M, Otley AR. Exclusive enteral nutrition for children with Crohn’s disease: use in Australia and attitudes of Australian paediatric gastroenterologists. J Paediatr Child Health. 2009;45:337–341.PubMedCrossRef Day AS, Stephenson T, Stewart M, Otley AR. Exclusive enteral nutrition for children with Crohn’s disease: use in Australia and attitudes of Australian paediatric gastroenterologists. J Paediatr Child Health. 2009;45:337–341.PubMedCrossRef
12.
go back to reference Day AS, Burgess L. Exclusive enteral nutrition and induction of remission of active Crohn’s disease in children. Expert Rev Clin Immunol. 2013;9:375–383; quiz 384. Day AS, Burgess L. Exclusive enteral nutrition and induction of remission of active Crohn’s disease in children. Expert Rev Clin Immunol. 2013;9:375–383; quiz 384.
13.
go back to reference Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn’s disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004;20:167–172.PubMedCrossRef Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn’s disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004;20:167–172.PubMedCrossRef
14.
go back to reference Ballinger A. Management of growth retardation in the young patient with Crohn’s disease. Expert Opin Pharmacother. 2002;3:1–7.PubMedCrossRef Ballinger A. Management of growth retardation in the young patient with Crohn’s disease. Expert Opin Pharmacother. 2002;3:1–7.PubMedCrossRef
15.
go back to reference Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2000;14:281–289.PubMedCrossRef Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2000;14:281–289.PubMedCrossRef
16.
go back to reference Werkstetter KJ, Schatz SB, Alberer M, Filipiak-Pittroff B, Koletzko S. Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohn’s disease patients. Ann Nutr Metab. 2013;63:10–16.PubMedCrossRef Werkstetter KJ, Schatz SB, Alberer M, Filipiak-Pittroff B, Koletzko S. Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohn’s disease patients. Ann Nutr Metab. 2013;63:10–16.PubMedCrossRef
17.
go back to reference Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;1:CD000542. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;1:CD000542.
18.
go back to reference Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30:501–507.PubMedCrossRef Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30:501–507.PubMedCrossRef
19.
go back to reference Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132:863–873; quiz 1165–1166. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132:863–873; quiz 1165–1166.
20.
go back to reference Siminoski K, O’Keeffe M, Levesque J, Hanley D, Brown JP. Canadian Association of Radiologists technical standards for bone mineral densitometry reporting. Can Assoc Radiol J. 2011;62:166–175.PubMedCrossRef Siminoski K, O’Keeffe M, Levesque J, Hanley D, Brown JP. Canadian Association of Radiologists technical standards for bone mineral densitometry reporting. Can Assoc Radiol J. 2011;62:166–175.PubMedCrossRef
21.
go back to reference Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res. 1992;7:137–145.PubMedCrossRef Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res. 1992;7:137–145.PubMedCrossRef
22.
go back to reference Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis. 2006;38:381–387. Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis. 2006;38:381–387.
23.
go back to reference Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18:509–523.PubMedCrossRef Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18:509–523.PubMedCrossRef
24.
go back to reference Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr. 2006;43:144–155.PubMedCrossRef Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr. 2006;43:144–155.PubMedCrossRef
25.
go back to reference Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn’s disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60:889–896.PubMedCrossRef Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn’s disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60:889–896.PubMedCrossRef
26.
go back to reference Lee SH, Jung JH, Choi SH, et al. Exercise intolerance in patients with atrial fibrillation: clinical and echocardiographic determinants of exercise capacity. J Am Soc Echocardiogr. 2005;18:1349–1354.PubMedCrossRef Lee SH, Jung JH, Choi SH, et al. Exercise intolerance in patients with atrial fibrillation: clinical and echocardiographic determinants of exercise capacity. J Am Soc Echocardiogr. 2005;18:1349–1354.PubMedCrossRef
27.
go back to reference Whitten KE, Leach ST, Bohane TD, Woodhead HJ, Day AS. Effect of exclusive enteral nutrition on bone turnover in children with Crohn’s disease. J Gastroenterol. 2010;45:399–405.PubMedCrossRef Whitten KE, Leach ST, Bohane TD, Woodhead HJ, Day AS. Effect of exclusive enteral nutrition on bone turnover in children with Crohn’s disease. J Gastroenterol. 2010;45:399–405.PubMedCrossRef
28.
go back to reference Royall D, Greenberg GR, Allard JP, Baker JP, Jeejeebhoy KN. Total enteral nutrition support improves body composition of patients with active Crohn’s disease. JPEN J Parenter Enteral Nutr. 1995;19:95–99.PubMedCrossRef Royall D, Greenberg GR, Allard JP, Baker JP, Jeejeebhoy KN. Total enteral nutrition support improves body composition of patients with active Crohn’s disease. JPEN J Parenter Enteral Nutr. 1995;19:95–99.PubMedCrossRef
29.
go back to reference Mascarenhas MR, Thayu M. Pediatric inflammatory bowel disease and bone health. Nutr Clin Pract. 2010;25:347–352.PubMedCrossRef Mascarenhas MR, Thayu M. Pediatric inflammatory bowel disease and bone health. Nutr Clin Pract. 2010;25:347–352.PubMedCrossRef
30.
go back to reference Navarro FA, Hanauer SB, Kirschner BS. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007;45:312–318.PubMedCrossRef Navarro FA, Hanauer SB, Kirschner BS. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007;45:312–318.PubMedCrossRef
31.
go back to reference Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res. 2004;19:1961–1968.PubMedCrossRef Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res. 2004;19:1961–1968.PubMedCrossRef
32.
go back to reference Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53:251–255.PubMedCrossRef Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53:251–255.PubMedCrossRef
33.
go back to reference van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777–787.PubMedCrossRef van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777–787.PubMedCrossRef
34.
go back to reference Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease. Gut. 2002;51:654–658.PubMedCrossRef Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease. Gut. 2002;51:654–658.PubMedCrossRef
35.
go back to reference Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn’s disease. Clin Nutr. 2005;24:775–779.PubMedCrossRef Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn’s disease. Clin Nutr. 2005;24:775–779.PubMedCrossRef
36.
go back to reference Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998;114:902–911.PubMedCrossRef Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998;114:902–911.PubMedCrossRef
37.
go back to reference Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory JW, Jenkins HR. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child. 1997;76:325–329.PubMedCrossRef Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory JW, Jenkins HR. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child. 1997;76:325–329.PubMedCrossRef
38.
go back to reference Rehman Q, Lane NE. Effect of glucocorticoids on bone density. Med Pediatr Oncol. 2003;41:212–216.PubMedCrossRef Rehman Q, Lane NE. Effect of glucocorticoids on bone density. Med Pediatr Oncol. 2003;41:212–216.PubMedCrossRef
39.
go back to reference Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol. 2003;98:1797–1801.PubMedCrossRef Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol. 2003;98:1797–1801.PubMedCrossRef
40.
go back to reference Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15:1267–1273.PubMedCrossRef Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15:1267–1273.PubMedCrossRef
41.
go back to reference Floren CH, Ahren B, Bengtsson M, Bartosik J, Obrant K. Bone mineral density in patients with Crohn’s disease during long-term treatment with azathioprine. J Intern Med. 1998;243:123–126.PubMedCrossRef Floren CH, Ahren B, Bengtsson M, Bartosik J, Obrant K. Bone mineral density in patients with Crohn’s disease during long-term treatment with azathioprine. J Intern Med. 1998;243:123–126.PubMedCrossRef
42.
go back to reference Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–266.PubMed Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–266.PubMed
43.
go back to reference de Zoeten EF, Pasternack BA, Mattei P, Kramerand RE, Kader HA. NASPGHAN clinical report and consensus statement: Diagnosis and Treatment of Perianal Crohns Disease. J Pediatr Gastroenterol Nutr. 2013. (Epub ahead of print). doi: 10.1097/MPG.0b013e3182a025ee. de Zoeten EF, Pasternack BA, Mattei P, Kramerand RE, Kader HA. NASPGHAN clinical report and consensus statement: Diagnosis and Treatment of Perianal Crohns Disease. J Pediatr Gastroenterol Nutr. 2013. (Epub ahead of print). doi: 10.​1097/​MPG.​0b013e3182a025ee​.
Metadata
Title
Use of Exclusive Enteral Nutrition Is Just as Effective as Corticosteroids in Newly Diagnosed Pediatric Crohn’s Disease
Authors
Jason Soo
Bushra A. Malik
Justine M. Turner
Rabin Persad
Eytan Wine
Kerry Siminoski
Hien Q. Huynh
Publication date
01-12-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2855-y

Other articles of this Issue 12/2013

Digestive Diseases and Sciences 12/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine